4E1RCAT
4E1RCAT 性质
| 沸点 | 764.8±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.423±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：≥5mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 4.23±0.10(Predicted) |
| 颜色 | 棕色至深棕色 |
4E1RCAT 用途与合成方法
IC50: ∼4 μM (eIF4E/eIF4G)
4E1RCat is an inhibitor of eIF4E:eIF4GI interaction, with an IC 50 an of ∼4 μM. 4E1RCat binding to eIF4E also interferes with eIF4G and 4E-BP binding. 4E1RCat inhibits ribosome recruitment to mRNA in a cap-dependent manner. 4E1RCat blocks the capped mRNA translation, and the translation is activated by CDK1/CYCB1. Nearly all new protein synthesis in both mitosis and interphase is cap-dependent and -sensitive to 4E1RCat treatment, in HeLa and U2OS cells.
4E1RCat (15 mg/kg, i.p.) affacts chemosensitivity of Pten +/- Eμ-Myc tumors in mice. 4E1RCat (15 mg/kg, i.p.) sensitizes Pten +/- Eμ-Myc and Tsc2 +/- Eμ-Myc lymphomas to the cytotoxic effects of doxorubicin (Dxr), and 4E1RCat targets translation in mice.
4E1RCAT 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-14427 | 1 mg | 363 | ||
| 2024-11-08 | HY-14427 | 4E1RCAT | 328998-25-0 | 5mg | 800 |
